循環器ジャーナル67巻4号

2019年10月発行

特集 冠動脈疾患のリスク管理のフロントライン Ⅲ．冠動脈疾患合併症をどう管理する？

心不全をどう防ぎ治療する？

著者： 竹石恭知¹

所属機関： ¹福島県立医科大学医学部循環器内科

ページ範囲：P.644 - P.654

Point
・心不全は進行性の病態であり，ステージを意識した治療方針の決定が必要である．
・冠危険因子管理，心臓リモデリング抑制，心筋虚血評価と血行再建，合併症管理が重要である．

参考文献

1) 平成29年簡易生命表の概況　https://www.mhlw.go.jp/toukei/saikin/hw/life/life17/dl/life17-02.pdf

2) Mosterd A, Hoes AW:Clinical epidemiology of heart failure. Heart 93:1137-1146, 2007

3) 厚生労働省：平成26年度（2014）患者調査の概況．https://www.mhlw.go.jp/toukei/saikin/hw/kanja/17/index.html

4) Shimokawa H, Miura M, Nochioka K, et al:Heart failure as a general pandemic in Asia. Eur J Heart Fail 17:884-892, 2015

5) van der Wal MH, Jaarsma T:Adherence in heart failure in the elderly:problem and possible solutions. Int J Cardiol 125:203-208, 2008

6) 筒井裕之，他：日本循環器学会/日本心不全学会合同ガイドライン．急性・慢性心不全診療ガイドライン（2017年改訂版）．2018　http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf

7) Yancy CW, Jessup M, Bozkurt B, et al:2013 ACCF/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128:e240-e327, 2013

8) Jong P, Yusuf S, Rousseau MF, et al:Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction:a follow-up study. Lancet 361:1843-1848, 2003

9) Breyer MD, Susztak K:The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov 15:568-588, 2016

10) Granger CB, McMurray JJ, Yusuf S, et al:Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:the CHARM-Alternative trial. Lancet 362:772-776, 2003

11) Cohn JN, Tognoni G:A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001

12) Pfeffer MA, McMurray JJ, Velazquez EJ, et al:Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893-1906, 2003

13) McMurray JJ, Ostergren J, Swedberg K, et al:Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-Added trial. Lancet 362:767-771, 2003

14) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction;the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001

15) Poole-Wilson PA, Swedberg K, Cleland JG, et al:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial（COMET）randomised controlled trial. Lancet 362:7-13, 2003

16) Rouleau JL, Roecker EB, Tendera M, et al:Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure:the Carvedilol Prospective Randomized Cumulative Survival（COPERNICUS）study. J Am Coll Cardiol 43:1423-1429, 2004

17) Packer M, Coats AJ, Fowler MB, et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001

18) Willenheimer R, van Veldhuisen DJ, Silke B, et al:Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence;results of the randomized cardiac insufficiency bisoprolol study（CIBIS）Ⅲ. Circulation 112:2426-2435, 2005

19) Pitt B, Zannad F, Remme WJ, et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717, 1999

20) Pitt B, Bakris G, Ruilope LM, et al:Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study（EPHESUS）. Circulation 118:1643-1650, 2008

21) Zannad F, McMurray JJ, Krum H, et al:Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11-21, 2011

22) Tsutsui H, Ito H, Kitakaze M, et al:Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure（J-EMPHASIS-HF）. Circ J 82:148-158, 2017

23) Brater DC:Diuretic therapy. N Engl J Med 339:387-395, 1998

24) Masuyama T, Tsujino T, Origasa H, et al:Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J 76:833-842, 2012

25) Konstam MA, Gheorghiade M, Burnett JC Jr, et al:Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST outcome trial. JAMA 297:1319-1331, 2007

26) EPOCH Study Group:Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure:the effects of pimobendan on chronic heart failure study（EPOCH study）. Circ J 66:149-157, 2002

27) Uretsky BF, Young JB, Shahidi FE, et al:Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure:results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 22:955-962, 1993

28) Packer M, Gheorghiade M, Young JB, et al:Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 329:1-7, 1993

29) Garg R, Gorlin R, Smith T, et al:The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525-533, 1997

30) Ouyang AJ, Lv YN, Zhong HL, et al:Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol 115:901-906, 2015

31) Vamos M, Erath JW, Hohnloser SH:Digoxin-associated mortality:a systematic review and meta-analysis of the literature. Eur Heart J 36:1831-1838, 2015

32) Packer M, O'Connor CM, Ghali JK, et al:Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335:1107-1114, 1996

33) Goldstein RE, Boccuzzi SJ, CruessD, et al:Diltiazem increases late-onset congestive heart failure in post infarction patients with early reduction in ejection fraction. The Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Circulation 83:52-60, 1991

34) Elkayam U, Johnson JV, Shotan A, et al:Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation 99:2652-2657, 1999

35) Redfield MM, Anstrom KJ, Levine JA, et al:Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 373:2314-2324, 2015

36) Taylor AL, Ziesche S, Yancy C, et al:Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351:2049-2057, 2004

37) Cleland JG, Swedberg K:Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet 351:1657-1658, 1998

38) McMurray JJ, Packer M, Desai AS, et al:Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993-1004, 2014

39) Tsutsui H, Momomura S, Saito Y, et al:Efficacy and safety of sacubitril/valsartan（LCZ696）in Japanese patients with chronic heart failure and reduced ejection fraction:Rationale for and design of the randomized, double-blind PARALLEL-HF study. J Cardiol 70:225-231, 2017

40) Diaz A, Bourassa MG, Guertin MC, et al:Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26:967-974, 2005

41) Fox K, Ford I, Steg PG, et al:Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction（BEAUTIFUL）:a randomised, double-blind, placebo-controlled trial. Lancet 372:807-816, 2008

42) Swedberg K, Komajda M, Böhm M, et al:Ivabradine and outcomes in chronic heart failure（SHIFT）:a randomised placebo-controlled study. Lancet 376:875-885, 2010

43) Ponikowski P, Voors AA, Anker SD, et al:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology（ESC）Developed with the special contribution of the Heart Failure Association（HFA）of the ESC. Eur Heart J 37:2129-2200, 2016

44) Yancy CW, Jessup M, Bozkurt B, et al:2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136:e137-e161, 2017

45) 野原隆司，安達　仁，石原俊一，他：循環器病の診断と治療に関するガイドライン（2011年度合同研究班報告）心血管疾患におけるリハビリテーションに関するガイドライン（2012年改訂版）．2012　http://www.j-circ.or.jp/guideline/pdf/JCS2012_nohara_h.pdf

46) O'Connor CM, Whellan DJ, Lee KL, et al:Efficacy and safety of exercise training in patients with chronic heart failure:HF-ACTION randomized controlled trial. JAMA 301:1439-1450, 2009

47) Taylor RS, Walker S, Smart NA, et al:Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure:Individual participant meta-analysis. J Am Coll Cardiol 73:1430-1443, 2019

48) Pandey A, Parashar A, Kumbhani DJ, et al:Exercise training in patients with heart failure and preserved ejection fraction:meta-analysis of randomized control trials. Circ Heart Fail 8:33-40, 2015

49) Holland R, Battersby J, Harvey I, et al:Systematic review of multidisciplinary interventions in heart failure. Heart 91:899-906, 2005

50) Schinkel AF, Bax JJ, Delegado V, et al:Clinical relevance of hibernating myocardium in ischemic left ventricular dysfunction. Am J Med 123:978-986, 2010

51) Velazquez EJ, Lee KL, Deja MA, et al:Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364:1607-1616, 2011

52) Velazquez EJ, Lee KL, Jones RH, et al:Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374:1511-1520, 2016

53) Bangalore S, Guo Y, Samadashvili Z, et al:Revascularization in patients with multivessel coronary artery disease and severe left ventricular systolic dysfunction:Everolimus-eluting stents versus coronary artery bypass graft surgery. Circulation 133:2132-2140, 2016

54) Nagendran J, Bozso SJ, Norris CM, et al:Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction. J Am Coll Cardiol 71:819-827, 2018